RESEARCH-USE BIOSIMILAR ANTIBODY

Vobramitamab

Antibody-drug conjugate · IgG1

B7H3IgG1RUO

Vobramitamab is a humanized B7-H3 monoclonal antibody (mAb). Vobramitamab conjugated with prodrug seco-DUBA (HY-132180A) via a cleavable linker, to form antibody-drug conjugate (ADC), the MGC018. MGC018 displays potent antitumor activity in preclinical tumor models of breast, ovarian, and lung cancer, as well as melanoma.

TARGETB7H3
YAntibody-drug conjugate
CATALOGSC-BS-037
CATALOG NUMBERSC-BS-037
MOLECULAR WEIGHTApprox. 144.691 kDa
PRODUCT FORMATAntibody-drug conjugate

A research-use configuration for comparative antibody studies

Vobramitamab is a humanized B7-H3 monoclonal antibody (mAb). Vobramitamab conjugated with prodrug seco-DUBA (HY-132180A) via a cleavable linker, to form antibody-drug conjugate (ADC), the MGC018. MGC018 displays potent antitumor activity in preclinical tumor models of breast, ovarian, and lung cancer, as well as melanoma.

Vobramitamab is a recombinant research-use antibody directed against B7H3.

START A CONVERSATION

Tell us about your research goals.

For quotes, sample requests or technical support, start with your target and experimental context.

Contact StellaCyte
Vobramitamab | StellaCyte